The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Open accessThe DOI matches its Crossref record; 335 of the 339 references it cites were found in a registry or an index.
Abstract
Transporter-mediated drug resistance is a major obstacle in anticancer drug delivery and a key reason for cancer drug therapy failure. Membrane solute carrier (SLC) transporters play a crucial role in the cellular uptake of drugs. The expression and function of the SLC transporters can be down-regulated in cancer cells, which limits the uptake of drugs into the tumor cells, resulting in the inefficiency of the drug therapy. In this review, we summarize the current understanding of low-SLC-transporter-expression-mediated drug resistance in different types of cancers. Recent advances in SLC-transporter-targeting strategies include the development of transporter-utilizing prodrugs and nanocarriers and the modulation of SLC transporter expression in cancer cells. These strategies will play an important role in the future development of anticancer drug therapies by enabling the efficient delivery of drugs into cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
(1989) · PubMed · Cited by 3,343
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
Hallmarks of cancer resistance
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · iScience · doi:10.1016/j.isci.2024.109979 · Cited by 149
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Zhong, L., Zhou, H., Tang, Z., Li, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02567-3 · Cited by 77
Barathan, M., Zulpa, A. K., Ng, S. L., Lokanathan, Y., Ng, M. H., & Law, J. X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137470 · Cited by 55
Current Advances in Nanocarriers for Cancer Therapy
Zeinali, R., Zaeifi, D., Zolfaghari-Moghaddam, S. Y., Paul, M. K., & Biazar, E. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s548088 · Cited by 48
Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers
Bharadwaj, R., Jaiswal, S., de la Cruz, E. V., & Thakare, R. (2024) · Diseases · doi:10.3390/diseases12030063 · Cited by 42
The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells
Wolf, G., Craigon, C., Teoh, S. T., Essletzbichler, P., Onstein, S., Cassidy, D. M., Uijttewaal, E. C. H., Dvorak, V., Cao, Y., Bensimon, A., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.11.009 · Cited by 37
Kim, M., Hong, W. C., Kang, H. W., Kim, J. H., Lee, D., Cheong, J., Jung, H., Kwon, W., Jang, J., Kim, H. J., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07476-5 · Cited by 29
The dual role of autophagy in suppressing and promoting hepatocellular carcinoma
Mohammed, W. H., Sulaiman, G. M., Abomughaid, M. M., Klionsky, D. J., & Abu-Alghayth, M. H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1472574 · Cited by 24
Drif, A. I., Yücer, R., Damiescu, R., Ali, N. T., Hagar, T. H. A., Avula, B., Khan, I. A., & Efferth, T. (2024) · Biomedicines · doi:10.3390/biomedicines12071484 · Cited by 21
Kiełbowski, K., Król, M., Bakinowska, E., & Pawlik, A. (2024) · Membranes · doi:10.3390/membranes14110223 · Cited by 20
Ma, C., Xu, A., Zuo, L., Li, Q., Fan, F., Hu, Y., & Sun, C. (2025) · Pharmaceuticals · doi:10.3390/ph18050640 · Cited by 21
Treatment of ovarian cancer: From the past to the new era (Review)
Alrosan, K., Alrosan, A. Z., Heilat, G. B., Alrousan, A. F., Gammoh, O., Alqudah, A. M., Madae’en, S., & Alrousan, M. (2025) · Oncology Letters · doi:10.3892/ol.2025.15130 · Cited by 21
Yeung, A. W. K., Solka, M., Jóźwik, A., Ksepka, N., Matin, M., Wang, D., Zielińska, A., MohanaSundaram, A., Véjux, A., Zarrouk, A., et al. (2024) · Animal Science Papers and Reports · doi:10.2478/aspr-2023-0020 · Cited by 16
A Review on the Role of Human Solute Carriers Transporters in Cancer
Hossen, M. S., Islam, M. S. U., Yasin, M., Ibrahim, M., & Das, A. (2025) · Health Science Reports · doi:10.1002/hsr2.70343 · Cited by 17
Is it still worth renewing nucleoside anticancer drugs nowadays?
Liu, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115987 · Cited by 14
Li, J., Zhang, L., Shang, Y., Liu, J., & Zhao, H. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70586 · Cited by 17
Zheng, L. T., Chang, R., Liang, B., Wang, Y., Zhu, Y., Jia, Z., Fan, J., Zhang, Z., Du, B., & Kong, D. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.107 · Cited by 16
Contribution and expression of renal drug transporters in renal cell carcinoma
Zuo, Y., Li, T., Yang, S., Chen, X., Tao, X., Dong, D., Liu, F., & Zhu, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466877 · Cited by 10
Chen, M., Li, W., Tao, Y., Hu, C., Ge, R., Kang, S., Yue, P., Man, C. H., Wang, L., & Yan, X. (2025) · Haematologica · doi:10.3324/haematol.2024.287269 · Cited by 12
Prognostic value of neutrophil extracellular trap signature in clear cell renal cell carcinoma
Li, R., Jiang, X., Wang, P., & Liu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1205713 · Cited by 10
Gastric cancer with brain metastasis: from molecular characteristics and treatment
Zhu, Y., Zhou, M., Li, C. F., Kong, W., & Hu, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1310325 · Cited by 11
Cho, S. Y., & Kang, N. S. (2024) · Cancers · doi:10.3390/cancers16183226 · Cited by 11
Comparative Analysis of Chemotherapy Resistance Mechanisms in Humans and Companion Animals
Cravo, D. L. D. M., Pimentel, P. A. B., Garcia, A. P. V., Junqueira, A. L. D. M., Soares, F. S., Giuliano, A., Almendros, A., & Horta, R. D. S. (2025) · Veterinary Sciences · doi:10.3390/vetsci12080747 · Cited by 8
Marı́n, J. J. G., Serrano, M. A., Herráez, E., Lozano, E., Ortiz-Rivero, S., Perez‐Silva, L., Reviejo, M., & Briz, Ó. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.42 · Cited by 7
Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies
Pan, C., & Lee, L. T. O. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189272 · Cited by 11
Feng, T., Wang, L., Zhou, R., Yu, J., Wang, S., Deng, X., Zhang, W., Wang, B., Li, F., & Ma, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-86841-y · Cited by 7
Role of solute carrier transporters in ovarian cancer (Review)
Quaresima, B., Scicchitano, S., Faniello, M. C., & Mesuraca, M. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5465 · Cited by 7
Radhakrishna, U., Radhakrishnan, R., Uppala, L. V., Muvvala, S. B., Prajapati, J., Rawal, R., Bahado-Singh, R. O., & Sadhasivam, S. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1442915 · Cited by 6
Wang, G., Jin, W., Zhang, L., Dong, M., Zhang, X., Zhou, Z., & Wang, X. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02261-3 · Cited by 6
Li, L., Wang, G., Xue, B., Li, X., Wang, J., Wang, W., Liu, C., Li, C., & Zheng, X. (2025) · ACS Materials Letters · doi:10.1021/acsmaterialslett.5c00097 · Cited by 5
Kitmür, İ., Mesci, S., Ay, E. B., Yıldırım, T., & Çiftçi, G. Y. (2025) · Inorganica Chimica Acta · doi:10.1016/j.ica.2025.122812 · Cited by 5
Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs
Boeckman, M., Drabison, T., Germakovski, A., Warmuth, A., Ahmed, B., Chowdhury, A. T., Hu, S., Sprowl, J. A., Sparreboom, A., & Huang, K. M. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100117 · Cited by 4
Fardel, O., Moreau, A., Carteret, J., Denizot, C., Vée, M. L., & Parmentier, Y. (2024) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-024-00902-7 · Cited by 4
Curtaz, C. J., Wucherpfennig, S., Al-Masnaea, E., Herbert, S.-L., Wöckel, A., Meybohm, P., & Burek, M. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1331126 · Cited by 4
An anti-neoplastic tale of metformin through its transport
Bhati, F. K., & Bhat, M. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123060 · Cited by 3
Li, C., Wang, Y., Liang, J., Haenen, G. R. M. M., Chen, Y., Li, Z., Zhang, M., & Dubois, L. J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47010036 · Cited by 3
Shahid, N., & Hammond, J. R. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100203 · Cited by 2
The Solute Carrier Superfamily as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma
Cho, S. Y., Eun, H. S., Kim, J., Ko, Y. D., Rou, W. S., & Joo, J. S. (2025) · Genes · doi:10.3390/genes16040463 · Cited by 2
Reduce drug uptake in the development of resistance
Alves, R., Jorge, J., Costa, M. I., Abrantes, A. M., Botelho, M. F., Gonçalves, A. C., & Sarmento‐Ribeiro, A. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21790-6.00015-8 · Cited by 1
McKenna, M., Linganathan, S., Li, A., Ruge, F., Lane, J., Ye, L., Jiang, W. G., & Hargest, R. (2025) · PubMed · doi:10.14670/hh-18-881 · Cited by 1
The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers
Sogawa, C. A., Shimada, K., & Nakano, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094310 · Cited by 1
Inhibition of purine nucleoside and nucleobase transporters by tyrosine kinase inhibitors
Shahid, N., Kim, C. H., Jabilona, K., Nguyen, K. H., Ruel, N. M., & Hammond, J. R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348426 · Cited by 1
Балан, О. В., Малышева, И. Е., Зарецкая, М. В., Марусенко, И. М., & Барышева, О. Ю. (2024) · Proceedings of the Karelian Research Centre of the Russian Academy of Sciences · doi:10.17076/eb1975
Synthesis and Characterization of New Monosubstituted Pillar[5]arene with Terminal Carboxyl Group
Yakimova, L. S., Filimonova, D., Nazarova, A., & Stoikov, I. I. (2025) · Molbank · doi:10.3390/m2004
Epigenetic-related drug resistance
Loren, P., & Salazar, L. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00043-8
Kostic, J., Dragičević, S., Miladinov, M., Rom, A. D., Bjelanovic, J., Kovač, J. D., Despotović, J., Babič, T., Ljubičić, J., Pavlovic, D., et al. (2025) · Annals of Human Genetics · doi:10.1111/ahg.70019
Therapeutic potential of solute carrier transporters in cervical squamous cell carcinoma
Cho, S. Y., Lee, Y. J., Ko, Y. D., Kim, T. J., & Lee, S. W. (2025) · Precision and Future Medicine · doi:10.23838/pfm.2025.00198
Metabolic zonation and characterization of tissue slices with spatial transcriptomicsPreprint
Arrastoa, O. E., Pirona, A. C., Wagner, A., & Yosef, N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.11.687271
GUPTA, S. K., Kumari, N. B., Saini, K. C., Singh, P., Chhabra, R., Bhardwaj, M., Grover, P., & Verma, M. (2023) · Research Square · doi:10.21203/rs.3.rs-2902713/v1
Asia Pacific journal of cancer biology
(n.d.) · RWTH Publications (RWTH Aachen)
Sarvepalli, M., Velidandi, A., Mishra, A., & Gutti, R. K. (2026) · Experientia supplementum · doi:10.1007/978-3-032-06948-1_3
Advances in Chemotherapeutic Potential of Glycoconjugates against Cancer
Kumar, R., Singh, A., Mazumder, A., Salahuddin, S., & Singh, N. (2026) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206401396251204070919
Conséquences des infections virales respiratoires sur le microenvironnement tumoral pulmonaire
Foy, P.-E. (2024) · theses.fr (ABES) · doi:10.70675/1985936fz59cdz44f0z8a80z18b14200f298
Solute carrier transporters in tumor metabolism and tumor immunity
Chen, M., Xu, J. F., Ma, H., Qin, J., Cheng, J., & Lv, J. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112084
Ribeiro, E., & Vale, N. (2026) · Membranes · doi:10.3390/membranes16070217
Clemente-Soto, A. F., Hernández, M. C., Duriez-Tizoc, N. L., Bernal-Reynaga, R., Maldonado‐Domínguez, M., Romero‐Ávila, M., Parra‐Unda, J. R., Delgado‐Vargas, F., & Martínez-Valenzuela, M. (2026) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2026.11.3.705
Advanced Nanocarriers for Cancer Therapies: Recent Developments and Clinical Challenges
Rehmani, A., Rahangdale, P. G., & Meshram, P. D. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i9.7989
Shadab, A. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05971-w
Mohammed, W. H., Sulaiman, G. M., & Mohammed, H. A. (2026) · Arabian Journal of Chemistry · doi:10.25259/ajc_346_2026
BindingDB Entry 50021754: Is it still worth renewing nucleoside anticancer drugs nowadays?
BindingDB (2025) · UC San Diego · doi:10.7270/q2f76j73
Research and application progress of siRNA nano-delivery systems in gliomas
He, M., Sun, F., Wu, L., Gao, Y., Wang, W., Dong, J., & Yan, J. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2756480
Adico, M. D. W., Coulibaly, T., Dagnogo, D., Savadogo, M., Daramcoum, W. A. M. P., Yao, S., Dago, D. N., Coulibaly, F. H., Snr, A. A. Z., Bayala, B., et al. (2026) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s629435
Metadata
- Authors
- Puris, E., Fricker, G., & Gynther, M.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Gynther, Mikko
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-01-21
- Volume
- 15
- Issue
- 2
- Pages
- 364
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9966068
- OpenAlex
- W4317733597
- Cited by
- 58
- References
- 339
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 19 · 2023: 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- solute carrier transporters, anticancer drug delivery, drug resistance, cancer cells, drug uptake, nanocarriers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.